Organon signs an exclusive, worldwide licence agreement on advanced antithrombotic compounds with Endotis Pharma

02-Nov-2007
Organon, the human healthcare business unit of Akzo Nobel, announced that it has signed an exclusive, worldwide license agreement with Endotis Pharma concerning the development and commercialization of several antithrombotic compounds. Endotis is a specialty pharma company dedicated to the discovery and development of small-glyco drugs for applications in thrombosis and oncology. Under the terms of the agreement, Endotis has acquired exclusive rights to develop and commercialize Org 42675, Org 217609 (a neutralizable follow-up of Org 42675) and Org 224283, three antithrombotic compounds with an innovative dual mechanism of action. Financial details are not disclosed. Org 42675 and Org 217609 display a new and original dual mechanism of action, combining blood coagulation factor Xa inhibition and thrombin inhibition. Org 42675 has successfully completed two phase I clinical trials. Org 224283 also displays an innovative dual mechanism of action, combining factor Xa inhibition and an antiplatelet effect, both effects being neutralizable by a specific antidote. Org 224283 is at a preclinical-stage of development.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances